Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REBECCA L MOROOSE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1972503159
CMS profile
362319
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$144,632.89

194 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $109,954.44 153
PFIZER INC. $22,451.22 27
Genentech USA, Inc. $11,086.35 10
E.R. Squibb & Sons, L.L.C. $990.00 1
PFIZER PHARMACEUTICALS LLC $116.42 1
JAZZ PHARMACEUTICALS INC. $17.26 1
Novartis Pharmaceuticals Corporation $17.20 1

Page 1 of 4; records 1–50 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REBECCA L MOROOSE

NPI 1972503159 · CMS profile ID 362319

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 4; records 1–50 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972503159?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REBECCA L MOROOSE, NPI 1972503159, CMS profile ID 362319. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 4; records 1–50 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972503159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). REBECCA L MOROOSE, NPI 1972503159, CMS profile ID 362319. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 4; records 1–50 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972503159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
REBECCA L MOROOSE, NPI 1972503159, CMS profile ID 362319, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 4; records 1–50 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1972503159?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

194 matching records · $144,632.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 194 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 194.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $1,137.0211/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681326995 CMS
Genentech USA, Inc. $30.4411/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681330925 CMS
Genentech USA, Inc. $140.6711/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681392903 CMS
Genentech USA, Inc. $4,160.0011/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681410677 CMS
Genentech USA, Inc. $78.1311/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681424155 CMS
PFIZER INC. $3,500.0011/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673827993 CMS
JAZZ PHARMACEUTICALS INC. $17.2611/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684157381 CMS
Lilly USA, LLC $2,800.0011/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658103693 CMS
Lilly USA, LLC $1,050.0011/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658117069 CMS
PFIZER INC. $90.0011/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673831329 CMS
Lilly USA, LLC $1,750.0011/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658103691 CMS
Lilly USA, LLC $2,800.0011/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658117067 CMS
Lilly USA, LLC $6.3011/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658093565 CMS
Lilly USA, LLC $78.7011/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658100191 CMS
Lilly USA, LLC $15.7411/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658113929 CMS
Lilly USA, LLC $196.6011/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658093541 CMS
PFIZER INC. $196.8111/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673145987 CMS
PFIZER INC. $2.0011/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673171719 CMS
PFIZER INC. $6.6311/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673176023 CMS
PFIZER INC. $9.9811/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673181315 CMS
PFIZER INC. $3,500.0011/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673648269 CMS
PFIZER INC. $532.2411/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673765097 CMS
Lilly USA, LLC $531.7010/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658117039 CMS
PFIZER INC. $161.4610/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673756969 CMS
PFIZER INC. $399.9210/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673705687 CMS
PFIZER INC. $92.8410/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673639071 CMS
Lilly USA, LLC $1,400.0010/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658096855 CMS
PFIZER INC. $537.1710/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672866007 CMS
PFIZER INC. $141.2210/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673173543 CMS
PFIZER INC. $133.2210/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673181883 CMS
PFIZER INC. $3,750.0010/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673182947 CMS
PFIZER INC. $9.2810/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672823699 CMS
PFIZER INC. $10.0010/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672975964 CMS
Lilly USA, LLC $48.7910/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658110487 CMS
Lilly USA, LLC $278.0010/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658113923 CMS
PFIZER INC. $208.3210/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672808021 CMS
PFIZER INC. $3,500.0010/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672928515 CMS
PFIZER PHARMACEUTICALS LLC $116.4210/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948911831 CMS
PFIZER INC. $64.9510/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672807613 CMS
PFIZER INC. $131.7609/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672823069 CMS
Genentech USA, Inc. $136.6609/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681129865 CMS
Genentech USA, Inc. $1,133.0609/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681129981 CMS
Genentech USA, Inc. $86.0909/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681357135 CMS
Genentech USA, Inc. $24.2809/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681370791 CMS
Genentech USA, Inc. $4,160.0009/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681412223 CMS
PFIZER INC. $391.4409/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673661005 CMS
Lilly USA, LLC $2,450.0009/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658103689 CMS
Lilly USA, LLC $2,800.0009/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658110485 CMS
Lilly USA, LLC $15.0009/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658093559 CMS
Lilly USA, LLC $9.0009/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658103687 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $144,632.89 194
PY2020 $112,144.11 149
PY2021 $126,523.25 106
PY2022 $157,739.91 136
PY2023 $1,619.58 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,773.40 2
PY2025 Principal investigator $23,429.00 2
PY2024 Recipient $3,047.65 1
PY2023 Recipient $4,115.87 1
PY2023 Principal investigator $488.00 1
PY2022 Principal investigator $30,225.68 18
PY2021 Recipient $3,820.00 2
PY2021 Principal investigator $107,576.56 28
PY2020 Principal investigator $105,271.83 68
PY2019 Principal investigator $147,188.91 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

84 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $11.00 12/11/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693405
Principal investigator 1 PFIZER INC. $11.00 12/11/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693429
Principal investigator 1 PFIZER INC. $45.00 12/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671695017
Principal investigator 1 PFIZER INC. $1,770.00 11/28/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671694965
Principal investigator 1 PFIZER INC. $11.00 11/21/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693427
Principal investigator 1 PFIZER INC. $50.00 11/14/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671657309
Principal investigator 1 PFIZER INC. $1,210.00 11/05/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671694961
Principal investigator 1 PFIZER INC. $45.00 11/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671695019
Principal investigator 1 Seattle Genetics, Inc. $8,641.00 10/18/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 709079121
Principal investigator 1 PFIZER INC. $11.00 10/14/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693453
Principal investigator 1 PFIZER INC. $45.00 10/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671695015
Principal investigator 1 PFIZER INC. $2,331.00 09/19/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671694963
Principal investigator 1 PFIZER INC. $11.00 09/18/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693403
Principal investigator 1 PFIZER INC. $11.00 09/18/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693451
Principal investigator 1 Seattle Genetics, Inc. $760.00 09/18/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678822007
Principal investigator 1 Seattle Genetics, Inc. $2,922.00 09/18/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678822009
Principal investigator 1 PFIZER INC. $705.00 09/03/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671657295
Principal investigator 1 PFIZER INC. $1,148.00 09/03/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671689815
Principal investigator 1 PFIZER INC. $431.00 09/03/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671689957
Principal investigator 1 PFIZER INC. $45.00 09/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671638117
Principal investigator 1 PFIZER INC. $1,121.00 08/26/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671694063
Principal investigator 1 PFIZER INC. $11.00 08/22/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693469
Principal investigator 1 PFIZER INC. $1,675.85 08/20/2019 Non-covered Recipient Entity
TRIO US INC
A PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED ANDOR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE No dispute reported 06/30/2026 671687021
Principal investigator 1 PFIZER INC. $45.00 08/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671637985
Principal investigator 1 PFIZER INC. $2,489.00 07/30/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671657311
Principal investigator 1 PFIZER INC. $11.00 07/24/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693467
Principal investigator 1 PFIZER INC. $1,148.00 07/22/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671689809
Principal investigator 1 PFIZER INC. $1,148.00 07/22/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671689811
Principal investigator 1 PFIZER INC. $431.00 07/22/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671689813
Principal investigator 1 Seattle Genetics, Inc. $10,415.00 07/22/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678822005
Principal investigator 1 PFIZER INC. $1,210.00 07/10/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671631241
Principal investigator 1 Seattle Genetics, Inc. $2,146.00 07/10/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678821997
Principal investigator 1 Seattle Genetics, Inc. $8,252.00 07/10/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678821999
Principal investigator 1 Seattle Genetics, Inc. $1,739.00 07/02/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678822001
Principal investigator 1 Seattle Genetics, Inc. $6,686.00 07/02/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678822003
Principal investigator 1 PFIZER INC. $45.00 07/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671637925
Principal investigator 1 PFIZER INC. $11.00 06/26/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693363
Principal investigator 1 PFIZER INC. $1,121.00 06/12/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671631199
Principal investigator 1 PFIZER INC. $1,148.00 06/03/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671636449
Principal investigator 1 PFIZER INC. $1,148.00 06/03/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671636497
Principal investigator 1 PFIZER INC. $1,148.00 06/03/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671636499
Principal investigator 1 PFIZER INC. $1,148.00 06/03/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671636527
Principal investigator 1 PFIZER INC. $431.00 06/03/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671636637
Principal investigator 1 PFIZER INC. $45.00 06/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671638055
Principal investigator 1 PFIZER INC. $2,500.00 05/31/2019 Non-covered Recipient Entity
TRIO US INC
A PHASE I OPENLABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB MDV3800 IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT No dispute reported 06/30/2026 671631201
Principal investigator 1 PFIZER INC. $11.00 05/30/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693383
Principal investigator 1 Seattle Genetics, Inc. $78.00 05/22/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678821983
Principal investigator 1 Seattle Genetics, Inc. $300.00 05/22/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678821985
Principal investigator 1 Seattle Genetics, Inc. $979.00 05/22/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678821989
Principal investigator 1 PFIZER INC. $1,210.00 05/07/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671631243
Principal investigator 1 PFIZER INC. $12,803.00 05/02/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671625487
Principal investigator 1 PFIZER INC. $11.00 05/02/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693361
Principal investigator 1 PFIZER INC. $45.00 05/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671637923
Principal investigator 1 PFIZER INC. $431.00 04/24/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671636495
Principal investigator 1 Seattle Genetics, Inc. $4,646.00 04/18/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678821995
Principal investigator 1 PFIZER INC. $1,121.00 04/08/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671620509
Principal investigator 1 PFIZER INC. $766.00 04/04/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671625485
Principal investigator 1 PFIZER INC. $11.00 04/04/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671693385
Principal investigator 1 PFIZER INC. $1,000.00 04/01/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671636493
Principal investigator 1 PFIZER INC. $45.00 04/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671637987
Principal investigator 1 PFIZER INC. $2,820.00 03/21/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671618977
Principal investigator 1 PFIZER INC. $1,210.00 03/12/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671620507
Principal investigator 1 PFIZER INC. $2,378.00 03/12/2019 Non-covered Recipient Entity
TRIO US INC
A PHASE I OPENLABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB MDV3800 IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT No dispute reported 06/30/2026 671631197
Principal investigator 1 PFIZER INC. $11.00 03/06/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671617631
Principal investigator 1 PFIZER INC. $45.00 03/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671638051
Principal investigator 1 PFIZER INC. $431.00 02/25/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671620997
Principal investigator 1 Seattle Genetics, Inc. $6,643.00 02/20/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678821987
Principal investigator 1 PFIZER INC. $1,121.00 02/14/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671621059
Principal investigator 1 PFIZER INC. $969.53 02/07/2019 Non-covered Recipient Entity
Orlando Health Inc
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671617589
Principal investigator 1 PFIZER INC. $7.50 02/06/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671617587
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,561.00 02/04/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY INC
MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE No dispute reported 06/30/2026 640728369
Principal investigator 1 PFIZER INC. $45.00 02/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671638053
Principal investigator 1 PFIZER INC. $300.00 01/31/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671695221
Principal investigator 1 PFIZER INC. $1,217.00 01/31/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671695401
Principal investigator 1 Seattle Genetics, Inc. $10,015.00 01/29/2019 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678821993
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,985.00 01/28/2019 Covered Recipient Teaching Hospital
ORLANDO HEALTH
TRINITI1 A PHASE I AND OR II SINGLE ARM OPEN LABEL STUDY OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS PLUS EXEMESTANE IN THE TREATMENT OF MEN AND POSTMENOPAUSAL WOMEN WITH HR PLUS HER2 LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON No dispute reported 06/30/2026 640707431
Principal investigator 1 PFIZER INC. $1,148.00 01/22/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671620947
Principal investigator 1 PFIZER INC. $1,148.00 01/22/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671620995
Principal investigator 1 PFIZER INC. $431.00 01/22/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671620999
Principal investigator 1 PFIZER INC. $431.00 01/22/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 671621001
Principal investigator 1 PFIZER INC. $2,306.00 01/15/2019 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671620505
Principal investigator 1 PFIZER INC. $7.50 01/09/2019 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671617553
Principal investigator 1 PFIZER INC. $969.53 01/08/2019 Non-covered Recipient Entity
Orlando Health Inc
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671617633
Principal investigator 1 PFIZER INC. $45.00 01/01/2019 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 671637989